H.C. Wainwright analyst Edward White lowered the firm’s price target on InflaRx to $6 from $8 and keeps a Buy rating on the shares. The analyst cites a later launch expectation for vilobelimab in pyoderma gangrenosum for the target drop. After design of the Phase 3 study was announced, White moved his launch expectation to 2026 from 2025. His vilobelimab in pyoderma gangrenosum sales estimate is $21M for that year.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IFRX:
- InflaRx provides update on planned Phase III study of vilobelimab
- InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients
- Biotech Alert: Searches spiking for these stocks today
- InflaRx Soar after Amending COVID-19 Treatment Agreement
- InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19
